打开APP

Roche公布与Isis关于舞蹈症的研究协议

  1. Isis
  2. Roche
  3. 舞蹈症

来源:生物谷 2013-04-11 10:21

2013年4月9日讯 /生物谷BIOON/ --Roche公司与Isis公司达成一项关于亨廷顿氏舞蹈病的合作协议。整个协议总价值高达3亿9千万美元之多。Roche公司计划将公司研发的治疗亨廷顿氏舞蹈病的新药与Isis公司研发的新型给药系统结合起来。

2013年4月9日讯 /生物谷BIOON/ --Roche公司与Isis公司达成一项关于亨廷顿氏舞蹈病的合作协议。整个协议总价值高达3亿9千万美元之多。Roche公司计划将公司研发的治疗亨廷顿氏舞蹈病的新药与Isis公司研发的新型给药系统结合起来。(生物谷Bioon.com)

详细英文报道:

Roche ($RHHBY) has stepped up with a $392 million deal designed to marry its work on new technology for delivering brain treatments with Isis' ($ISIS) antisense programs for Huntington's disease. In the deal, the latest in a lengthy string for the Carlsbad, CA-based biotech company, Isis gains $30 million upfront with the rest payable on promised milestones.

The first step of this new collaboration will be devoted to Isis' lead therapy designed to scramble the Huntington's protein as well as follow-up therapies that target various forms of the Huntington's protein, possibly opening a path to new treatments for specific patient groups. And in a tandem move investigators will join forces to develop another program, combining Roche's "brain shuttle" technology for delivery through the blood-brain barrier--which it's been using in antibody research--to allow for systemic treatment of asymptomatic Huntington's patients.

In this early-stage partnership Roche retains the option of licensing the drugs through Phase I, taking over all responsibility for the rest of the clinical programs, with an eye to marching quickly to pivotal studies.

"Central to the partnership is Roche's brain shuttle program, which we see as highly complementary to Isis' drug development work," says Shafique Virani, the global head of neuroscience, cardiovascular and metabolism at Roche Partnering. "This dual track development program ensures whichever candidate compound proves to be most promising--Isis' lead target or Roche's brain shuttle version--can be taken forward to pivotal clinical trials."

Isis has been racking up a string of deals. Biogen Idec ($BIIB) stepped up for three pacts last year with more than a billion dollars. And AstraZeneca ($AZN) stepped up with a $31 million upfront late last year to partner on 5 cancer programs.

This latest deal is also a winner for the CHDI Foundation, which has been working with Isis on Huntington's disease. The foundation will get $1.5 million of the Roche cash along with a payout of its investment in the work through the milestones in the deal package.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->